EMEA-002540-PIP01-18 - paediatric investigation plan

Istradefylline

Key facts

• Active Substance:
  Istradefylline
• Therapeutic area:
  Neurology
• Decision number:
  P/0270/2019
• PIP number:
  EMEA-002540-PIP01-18
• Pharmaceutical form(s):
  Tablet
• Condition(s) / indication(s):
  Treatment of Parkinson's disease
• Route(s) of administration:
  Oral use
• Contact for public enquiries:

  Kyowa Kirin Limited

  E-mail: [e-mail]; Tel. [phone]

• Decision type:
  W: decision granting a waiver in all age groups for all conditions or indications
• Decision date:
  14/08/2019

Decision

P/0270/2019: EMA decision of 14 August 2019 on the granting of a product specific waiver for istradefylline (EMEA-002540-PIP01-18)

AdoptedReference Number: EMA/392859/2019